Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).
about
New developments in atherosclerosis: clinical potential of PCSK9 inhibitionTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainIdentification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein ReceptorThe multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functionsPhysiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.PCSK9 targets important for lipid metabolismProprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblastsPCSK9 as a therapeutic target for cardiovascular disease.Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.Quantitative characterization of the mechanism of action and impact of a 'proteolysis-permitting' anti-PCSK9 antibody.APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.
P2860
Q26783407-8FF2DD5A-ED76-4971-961E-C17DE91DA791Q27339783-5A83CB9E-8AA8-4F41-A740-EFAA5426E35BQ27680601-B03673D2-E728-4D57-ACF5-9039C4AC8A9DQ30541820-A5ACD6B7-1924-4A60-AC3C-ED6699FF950DQ33599961-107E283C-504A-479B-8608-A7D7C7CDF277Q34430377-EACBA298-76AA-436C-9E20-A3071401085CQ34458693-AEC42A51-BA34-411A-AED1-F6B92684BF86Q35612555-08BD3DC5-C67E-4241-BC83-6BD759F1B8EEQ35883857-592F7F47-9D3A-42C6-AD72-F3EB469D9399Q36035643-44A5ABBF-7062-4E91-AE66-2B8CF7E6041BQ37688760-1900FA41-CDE6-4E18-AD64-4C4D9ED72FB1Q37703261-75B088FA-8480-47C2-981D-037BD29D2E43Q38109960-EBA2867B-17C3-4835-9B03-6F14720D8D21Q39030028-4B00F18E-FD08-4C66-A902-67634C9E502BQ39051108-C755DE04-A93A-4277-B5BE-B7A9E6234B35Q41822823-1FD0DD8A-38AD-44EF-ADD7-6416E5D29173Q41917702-6B196793-DD88-4266-8783-7BED6CAEF5C3Q42323238-2FF8783A-0E31-4AB6-A85E-445E7E4AA48CQ51007815-9FA01D9C-A1C2-4217-8E91-DF512CA6D7C0
P2860
Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Characterization of proprotein ...... cursor-like protein 2 (APLP2).
@en
Characterization of proprotein convertase subtilisin/kexin type 9
@nl
type
label
Characterization of proprotein ...... cursor-like protein 2 (APLP2).
@en
Characterization of proprotein convertase subtilisin/kexin type 9
@nl
prefLabel
Characterization of proprotein ...... cursor-like protein 2 (APLP2).
@en
Characterization of proprotein convertase subtilisin/kexin type 9
@nl
P2093
P2860
P356
P1476
Characterization of proprotein ...... cursor-like protein 2 (APLP2).
@en
P2093
David L Shelton
Hong Liang
Rachel M DeVay
P2860
P304
10805-10818
P356
10.1074/JBC.M113.453373
P407
P577
2013-02-19T00:00:00Z